VivoSeq
Other

Immunogenicity

0

Pipeline Programs↗

166

Active Trials↗

136

Companies Involved↗

Immunogenicity is an early-stage landscape with 0 programs across 136 companies. The most active players are GSK, Sanofi, Merck & Co..

Intelligence

Pipeline Metrics

Competitive Density

66/100

Pipeline Velocity

74/100

Mech. Concentration

N/A

Completion Rate

94/100

Attrition Rate

5/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

GSK logo

GSK

0 programs

PreclinicalSanofi logo

Sanofi

0 programs

PreclinicalMerck & Co. logo

Merck & Co.

0 programs

PreclinicalPfizer logo

Pfizer

0 programs

PreclinicalNovartis logo

Novartis

0 programs

PreclinicalJohnson & Johnson logo

Johnson & Johnson

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

1,682

clinical trials

Completed1,298 · 77%
Unknown status130 · 8%
Recruiting64 · 4%
Active, not recruiting61 · 4%
Terminated50 · 3%
Not yet recruiting38 · 2%
Other41 · 2%

Clinical Trials

Trial Activity

1682 trials

A Study Evaluating the Safety and Immunogenicity of MVA Strain Monkeypox Attenuated Live Vaccine
Recruiting·SShanghai Institute Of Biological Products·Phase 1·NCT06771479·120 enrolled
A Study to Evaluate the Safety, Immunogenicity, and Pharmacokinetics of GR2102 in Healthy Adult
Recruiting·GGenrix (Shanghai) Biopharmaceutical Co., Ltd.·Phase 1·NCT06313697·132 enrolled
Safety, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Ascending Doses BCD-261 in Healthy Subjects
Recruiting·BBiocad·Phase 1·NCT06715540·48 enrolled
To Evaluate the Safety and Immunogenicity of 15-valent HPV Recombinant Vaccine in Chinese People Aged 9-45 Years
Recruiting·SShanghai Bovax Biotechnology Co., Ltd.·Phase 2·NCT06756269·330 enrolled
Evaluate the Efficacy, Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females
Recruiting·SShanghai Bovax Biotechnology Co., Ltd.·Phase 3·NCT04422366·8,000 enrolled
Assessment of Immunogenicity, Reactogenicity and Safety of the Drug GNG-DE in Comparison With the Reference Drug
Recruiting·NNPO Petrovax·Phase 3·NCT06834100·240 enrolled
A Phase III Clinical Trail to Evaluate the Efficacy, Safety, Pharmacokinetics and Immunogenicity Characteristics of GR2001 Injection
Recruiting·GGenrix (Shanghai) Biopharmaceutical Co., Ltd.·Phase 3·NCT06635798·582 enrolled
Evaluate the Safety and Immunogenicity After MG1111(BARICELA Inj.) as 2nd Vaccination in 4 ~ 6 Year Old Healthy Children With a History of 1st Varicella Vaccination
Recruiting·GGreen Cross Corporation·Phase 2·NCT05422508·230 enrolled
First-in-human Safety and Immunogenicity Study of SCB-1022 and SCB-1033 in Healthy Older Adults
Recruiting·CClover Biopharmaceuticals AUS Pty·Phase 1·NCT06984094·192 enrolled
Safety and Immunogenicity of Ervebo® and Zabdeno® Booster Vaccines Against Ebola Virus Following Previous Vaccination with the Zabdeno/Mvabea® or Ervebo® Vaccine Schedules in DRC
Recruiting·IInstitute of Tropical Medicine, Belgium·Phase 3·NCT06126822·624 enrolled
A Safety and Immunogenicity Study of CHIKV VLP Vaccine in Children.
Recruiting·—·Phase 3·NCT07003984·720 enrolled
Pharmacokinetic, Safety, Tolerability, and Immunogenicity Comparison of CKD-704 (Risankizumab Biosimilar), With EU-approved Skyrizi®, and US-licensed Skyrizi® in Healthy Adult Participants
Recruiting·Chong Kun Dang Pharmaceutical logoChong Kun Dang Pharmaceutical·Phase 1·NCT07258745·213 enrolled
A Study to Evaluate the Safety, Efficacy, PK, PD and Immunogenicity of Cipaglucosidase Alfa/Miglustat in IOPD Subjects Aged 0 to <18
Recruiting·AAmicus Therapeutics·Phase 3·NCT04808505·36 enrolled
RSV Immunogenicity Study in the Elderly (RISE)
Recruiting·—·Phase 3·NCT07203365·65 enrolled
Real-world Effectiveness, Safety and Immunogenicity of Chikungunya Vaccination in Populations at Risk of Severe or Complicated Forms: Prospective Study in La Réunion
Recruiting·—·Phase 4·NCT06928753·1,800 enrolled
Page 1 of 113

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)